IL33 and hepatocellular carcinoma: Recently, the IL-33-TGF-β niche signaling loop and IL-34-CD36 axis between CSCs and TAMs has been reported to promote immunosuppressive TAMs and therapeutic resistance in mouse models with squamous cell carcinoma or HCC with p53 inactivation [100, 219].